Liver X Receptor Agonist GW3965 Regulates Synaptic Function upon Amyloid Beta Exposure in Hippocampal Neurons
- 147 Downloads
Alzheimer’s disease (AD) is a devastating neurodegenerative disease characterized by beta-amyloid (Aβ) accumulation and neurofibrillary tangles formation in the brain which are associated to synaptic deficits and dementia. Liver X receptor (LXR) agonists have been demonstrated to revert of pathologic and cognitive defects in murine models of AD through the regulation of Apolipoprotein E, ATP-Binding Cassette A1 (ABCA1), by dampening neuroinflammation and also by reducing the levels of amyloid-β (Aβ) accumulation in the brain. However, the role of LXR with regard to the regulation of synaptic function remains relatively understudied. In the present paper, we analyzed the in-vitro effect of the LXR agonist GW3965 on synaptic function upon exposure of primary hippocampal cultures to oligomeric amyloid-β (oAβ(1–42)). We showed that oAβ(1–42) exposure significantly decreased the density of mature (mushroom shaped) dendritic spines density and synaptic contacts number. oAβ(1–42) also modulates the expression of pre- (VGlut1, SYT1, SV2A) and post-synaptic (SHANK2, NMDA) proteins, it decreases the expression of PINK1, and increases ROCKII, and activates of caspase-3; these changes were prevented by the pre-treating neuronal cultures with GW3965. These results show further support the role of the LXR agonist GW3965 in synaptic physiology and highlight its potential as an alternative pharmacological strategy for AD.
KeywordsAlzheimer’s disease Hippocampal neurons Synapsis Amyloid-β Liver X receptors GW3965
Contribution of Each Author
Báez-Becerra C: performed most experiments and contributed to manuscript writing.
Filipello F: performed dendritic spine analysis.
Sandoval-Hernández A: performed western blott experiments.
Arboleda H: contributed to desing of the experiments and writing of the manuscript.
Arboleda G: desing the experiments and wrote the manuscript.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- Alberdi E, Sáncer-Gómez MV, Cavaliere F, Pérez-Samartín A, Zugaza JL, Trullas R, Domercq M, Matute C (2010) Amyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47(3):264–272. https://doi.org/10.1016/j.ceca.2009.12.010 CrossRefPubMedGoogle Scholar
- Bittner T, Fuhrmann M, Burgold S, Ochs SM, Hoffmann N, Mitteregger G, Kretzschmar H, LaFerla FM, Herms J (2010) Multiple events lead to dendritic spine loss in triple transgenic Alzheimer’s disease mice. PLoS One 5(11):e15477. https://doi.org/10.1371/journal.pone.0015477 CrossRefPubMedPubMedCentralGoogle Scholar
- Chen J, Zacharek A, Cui X, Shehadah A, Jiang H, Roberts C, Lu M, Chopp M (2010) Treatment of stroke with a synthetic liver X receptor agonist, TO901317, promotes synaptic plasticity and axonal regeneration in mice. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 30(1):102–109. https://doi.org/10.1038/jcbfm.2009.187 CrossRefGoogle Scholar
- Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL (2010) ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 285(44):34144–34154. https://doi.org/10.1074/jbc.M110.108100 CrossRefPubMedPubMedCentralGoogle Scholar
- Du F, Yu Q, Yan S, Hu G, Lue LF, Walker DG, Wu L, Yan SF, Tieu K, Yan SS (2017) PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease. Brain. https://doi.org/10.1093/brain/awx258
- Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12:383–388Google Scholar
- Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58:681–693CrossRefPubMedPubMedCentralGoogle Scholar
- Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S (2008) Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 29:1619–1630CrossRefPubMedGoogle Scholar
- Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci Off J Soc Neurosci 27(4):796–807. https://doi.org/10.1523/JNEUROSCI.3501-06.2007 CrossRefGoogle Scholar
- Pearlstein E, Michel FJ, Save L, Ferrari DC, Hammond C (2016) Abnormal development of glutamatergic synapses afferent to dopaminergic neurons of the Pink1(−/−) mouse model of Parkinson’s disease. Front Cell Neurosci 23:168Google Scholar
- Sandoval-Hernández AG, Hernández HG, Restrepo A, Muñoz JI, Bayon GF, Fernández AF, Fraga MF, Cardona-Gómez GP, Arboleda H, Arboleda G (2016) Liver X receptor agonist modifies the DNA methylation profile of synapse and neurogenesis-related genes in the triple transgenic mouse model of Alzheimer’s disease. J Mol Neurosci 58(2):243–253. https://doi.org/10.1007/s12031-015-0665-8 CrossRefPubMedGoogle Scholar
- Vanmierlo T, Rutten K, Dederen J, Bloks VW, van Vark-van der Zee LC, Kuipers F, Kiliaan A, Blokland A, Sijbrands EJ, Steinbusch H, Prickaerts J, Lütjohann D, Mulder M (2011) Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol Aging 32:1262–1272CrossRefPubMedGoogle Scholar
- Yuste R (2015) The discovery of dendritic spines. Front Neuroanat 9:2–7Google Scholar